Phenominer Database Results (56 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Record ID Study ID
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum triglyceride level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood triglyceride amount male 218 days 11 113.5 mg/dl 4.81 15.95 serum triglyceride analysis 0 0 Wako Pure Chemicals, Tokyo, Japan 13194 311
F344/NSlc mesenteric fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 7 7.0 g 0.7 1.85 post excision weight measurement 0 12780 311
F344/NSlc epididymal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 7 10.4 g 0.7 1.85 post excision weight measurement 0 12782 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum total cholesterol level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood cholesterol amount male 218 days 7 65.8 mg/dl 2.93 7.75 serum total cholesterol measurement test 0 0 Wako Pure Chemicals, Tokyo, Japan 12787 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj epididymal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 7 5.5 g 0.5 1.32 post excision weight measurement 0 12790 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum total cholesterol level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood cholesterol amount male 218 days 11 72.7 mg/dl 2.13 7.06 serum total cholesterol measurement test 0.0 0 Wako Pure Chemicals, Tokyo, Japan 12793 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj epididymal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 11 10.6 g 0.3 0.99 post excision weight measurement 0 12796 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj retroperitoneal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 11 8.8 % 0.3 0.99 post excision weight measurement 0.0 0 67474 311
F344/NSlc serum total cholesterol level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood cholesterol amount male 218 days 7 69.7 mg/dl 1.77 4.68 serum total cholesterol measurement test 0 0 Wako Pure Chemicals, Tokyo, Japan 12775 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj blood glucose level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood glucose amount male 211 days 11 82.5 mg/dl 3.5 11.61 oral glucose tolerance test 0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 12792 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj mesenteric fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 11 7.6 g 0.3 0.99 post excision weight measurement 0 12800 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum free fatty acids level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood free fatty acid amount male 218 days 7 0.75 mmol/l 0.05 0.14 serum free fatty acid analysis 0.0 0 Wako Pure Chemicals, Tokyo, Japan 67496 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj mesenteric fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 11 2.06 % 0.09 0.3 post excision weight measurement 0.0 0 67469 311
F344/NSlc serum insulin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood insulin amount male 211 days 7 0.0 mg/dl 0.0 0.0 oral glucose tolerance test 0.0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67475 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum leptin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood leptin amount male 211 days 11 5.82 ng/ml 0.59 1.96 enzyme linked immunosorbent assay 0.0 oral glucose 7 days ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67486 311
F344/NSlc serum triglyceride level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood triglyceride amount male 218 days 7 108.4 mg/dl 14.5 38.36 serum triglyceride analysis 0 0 Wako Pure Chemicals, Tokyo, Japan 13192 311
F344/NSlc blood glucose level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood glucose amount male 211 days 7 78.0 mg/dl 2.6 6.88 oral glucose tolerance test 0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 12770 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj mesenteric fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 7 4.4 g 0.7 1.85 post excision weight measurement 0 12788 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj blood glucose level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood glucose amount male 211 days 11 87.7 mg/dl 3.2 10.61 oral glucose tolerance test 0.0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 12798 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj retroperitoneal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 11 8.8 g 0.3 0.99 post excision weight measurement 0 12801 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj retroperitoneal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 11 2.47 % 0.09 0.3 post excision weight measurement 0.0 0 67473 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum adiponectin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood adiponectin amount male 211 days 7 3.03 ng/ml 0.23 0.61 enzyme linked immunosorbent assay 0.0 0 ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67480 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum adiponectin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood adiponectin amount male 211 days 11 3.02 ng/ml 0.15 0.5 enzyme linked immunosorbent assay 0.0 0 ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67481 311
F344/NSlc serum leptin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood leptin amount male 211 days 7 5.46 ng/ml 1.06 2.8 enzyme linked immunosorbent assay 0.0 oral glucose 7 days ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67483 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum leptin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood leptin amount male 211 days 7 2.8 ng/ml 0.54 1.43 enzyme linked immunosorbent assay 0.0 oral glucose 7 days ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67484 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum leptin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood leptin amount male 211 days 11 6.28 ng/ml 0.51 1.69 enzyme linked immunosorbent assay 0.0 oral glucose 7 days ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67485 311
F344/NSlc epididymal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 7 2.63 % 0.16 0.42 post excision weight measurement 0.0 0 67491 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj epididymal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 7 1.48 % 0.12 0.32 post excision weight measurement 0.0 0 67492 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum free fatty acids level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood free fatty acid amount male 218 days 11 0.68 mmol/l 0.05 0.15 serum free fatty acid analysis 0.0 0 Wako Pure Chemicals, Tokyo, Japan 67498 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum triglyceride level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood triglyceride amount male 218 days 11 111.7 mg/dl 8.83 29.29 serum triglyceride analysis 0.0 0 Wako Pure Chemicals, Tokyo, Japan 13195 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj body weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. body mass male 211 days 11 423.2 g 7.3 24.21 body weighing method 0.0 oral glucose 0 min 12803 311
F344/NSlc mesenteric fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 7 1.77 % 0.15 0.4 post excision weight measurement 0.0 0 67467 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj mesenteric fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 7 1.18 % 0.15 0.4 post excision weight measurement 0.0 0 67468 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj mesenteric fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 11 1.81 % 0.07 0.23 post excision weight measurement 0.0 0 67470 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum insulin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood insulin amount male 211 days 11 0.0 mg/dl 0.0 0.0 oral glucose tolerance test 0.0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67477 311
F344/NSlc serum adiponectin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood adiponectin amount male 211 days 7 3.28 ng/ml 0.3 0.79 enzyme linked immunosorbent assay 0.0 0 ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67479 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj epididymal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 11 2.49 % 0.06 0.2 post excision weight measurement 0.0 0 67493 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj epididymal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 11 2.08 % 0.05 0.17 post excision weight measurement 0.0 0 67494 311
F344/NSlc serum free fatty acids level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood free fatty acid amount male 218 days 7 0.67 mmol/l 0.07 0.18 serum free fatty acid analysis 0.0 0 Wako Pure Chemicals, Tokyo, Japan 67495 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum triglyceride level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood triglyceride amount male 218 days 7 89.9 mg/dl 6.73 17.81 serum triglyceride analysis 0 0 Wako Pure Chemicals, Tokyo, Japan 13193 311
F344/NSlc retroperitoneal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 7 8.7 g 0.8 2.12 post excision weight measurement 0 12781 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj blood glucose level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood glucose amount male 211 days 7 78.7 mg/dl 3.4 9.0 oral glucose tolerance test 0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 12786 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj body weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. body mass male 211 days 11 425.3 g 5.3 17.58 body weighing method 0.0 oral glucose 0 min 12797 311
F344/NSlc body weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. body mass male 211 days 7 393.6 g 6.2 16.4 body weighing method oral glucose 0 min 12785 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj body weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. body mass male 211 days 7 368.7 g 8.7 23.02 body weighing method oral glucose 0 min 12791 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj mesenteric fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. mesenteric fat pad mass male 218 days 11 8.8 g 0.4 1.33 post excision weight measurement 0 12794 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum total cholesterol level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood cholesterol amount male 218 days 11 76.2 mg/dl 1.79 5.94 serum total cholesterol measurement test 0.0 0 Wako Pure Chemicals, Tokyo, Japan 12799 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj epididymal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. epididymal fat pad mass male 218 days 11 8.8 g 0.3 0.99 post excision weight measurement 0 12802 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj serum free fatty acids level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood free fatty acid amount male 218 days 11 0.66 mmol/l 0.05 0.16 serum free fatty acid analysis 0.0 0 Wako Pure Chemicals, Tokyo, Japan 67497 311
F344/NSlc retroperitoneal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 7 2.19 % 0.18 0.48 post excision weight measurement 0.0 0 67471 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj retroperitoneal fat pad weight to body weight ratio specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 7 1.48 % 0.13 0.34 post excision weight measurement 0.0 0 67472 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj serum insulin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood insulin amount male 211 days 7 0.0 mg/dl 0.0 0.0 oral glucose tolerance test 0.0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67476 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum insulin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood insulin amount male 211 days 11 0.0 mg/dl 0.0 0.0 oral glucose tolerance test 0.0 oral glucose 0 min ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67478 311
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj serum adiponectin level specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. blood adiponectin amount male 211 days 11 2.75 ng/ml 0.2 0.66 enzyme linked immunosorbent assay 0.0 0 ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) 67482 311
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj retroperitoneal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 7 5.5 g 0.5 1.32 post excision weight measurement 0 12789 311
F344.OLETF-(D14Rat23-D14Rat12)/Tj retroperitoneal fat pad weight specific pathogen-free condition (for 210 days) then fasting (for 1 days) Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. retroperitoneal fat pad mass male 218 days 11 10.5 g 0.4 1.33 post excision weight measurement 0 12795 311